ARTICLE | Clinical News
CMX-2043: Phase IIa data
July 4, 2011 7:00 AM UTC
Top-line data from a double-blind, placebo-controlled Phase IIa trial in patients undergoing PCI showed that IV CMX-2043 demonstrated a favorable safety profile at all 3 dose levels tested, which Isch...